Faculty | Presenters

Our esteemed faculty for the HTRS 2023 accredited educational program is a dynamic group of clinicians, physician-scientists, and basic/translational science researchers from both the U.S. and the international H&T community.
 

Dr. Arepally is Professor of Medicine and Vice Chief of Research in the Division of Hematology at Duke University. She received her medical degree from Vanderbilt University School of Medicine and completed her residency in Internal Medicine at Emory University Hospitals. She received her sub-specialty training in Hematology and Oncology at the University of Pennsylvania, where she developed her clinical and research interests in disorders of hemostasis and thrombosis. Her clinical interests are in immune-mediated thrombocytopenias and/or thrombotic disorders, including heparin-induced thrombocytopenia (HIT), immune thrombocytopenia (ITP), thrombotic thrombocytopenic purpura (TTP) and the recently described vaccine-induced immune thrombotic thrombocytopenia (VITT). Her long-standing research program investigates the pathogenesis of HIT. Contributions from her laboratory include the development of tools and models for studies of HIT and recent discoveries relating to the role of complement activation in the immune and thrombotic complications of HIT.

Dr. Lee is Research Assistant Professor at the University of North Carolina at Chapel Hill, and a member of the UNC Blood Research Center. His research interests include platelet signaling, antiplatelet therapy, and platelet transfusion.

Dr. Shavit is Professor of Pediatrics at the University of Michigan (UM). He received his BS at UM, followed by his MD and PhD from Northwestern University. Dr. Shavit returned to UM and completed a residency in pediatrics and a fellowship in pediatric hematology/oncology. During his fellowship, he developed vertebrate animal models to analyze the complex genetics underlying blood coagulation disorders in the laboratory of Dr. David Ginsburg. His initial work identified genetic modifier loci that regulate von Willebrand factor levels in mice. He then converted his studies to zebrafish in order to leverage its robust genetics. Dr. Shavit’s laboratory has performed genome editing with zinc finger nucleases, TALENs, and CRISPR to produce zebrafish models of pathologic hemorrhage, thrombosis, thrombopoiesis, and estrogen-induced thrombosis. The results have demonstrated that fish with coagulation factor deficiencies develop phenotypes analogous to those in the corresponding human diseases. Dr. Shavit cares for patients with coagulation disorders. Postdoctoral fellowships are currently available in his laboratory.

Dr. Davila is Co-Director of the Hemophilia Treatment Center at Montefiore, Director of the Hemostasis Thrombosis Program and Attending Physician at Children’s Hospital at Montefiore, and Assistant Professor at Albert Einstein College of Medicine in Bronx, New York. Dr. Davila trained in pediatrics at the State of New York (SUNY) Downstate Medical Center in Brooklyn, New York. She completed fellowships in pediatric hematology/oncology at Memorial Sloan Kettering Cancer Center/Weill-Cornell Medical College in New York, New York. Dr. Davila specializes in the diagnosis and management of children with thrombosis, hemophilia, and rare bleeding disorders. Her research focuses on efforts to improve thrombosis risk assessment in pediatric patients as well as the use of direct oral anticoagulants in the pediatric population.

Dr. Moll received his medical degree from Freiburg University in Germany. He completed his internship, residency, and fellowship in internal medicine and hematology/oncology at Duke University Medical Center in North Carolina, along with a one-year Clinical Coagulation Fellowship at the University of North Carolina at Chapel Hill. Dr. Moll is a faculty member at UNC in the Department of Medicine/Division of Hematology since 1999. His clinical interest is coagulation and classical hematology, with a particular focus on thrombosis and anticoagulation. Dr. Moll’s research interests include clinical trials on new anticoagulants and better use of established anticoagulants. He takes special interest in the clinical-medical education of patients, the public, and healthcare professionals. His four main professional goals for the next 5-10 years are: (1) to enhance national and local health care provider and patient education activities on venous thromboembolism, (2) to continue to build an “Athletes and Blood Clot Program”, (3) to support trainees in their career development in the field of coagulation/hematology, and (4) to work on identifying the etiology and best treatment of livedoid vasculopathy.

Dr. Kahn is a clinical epidemiologist and internist based at the Jewish General Hospital in Montreal, Canada, where she is the founder and Director of the Centre of Excellence in Thrombosis and Anticoagulation Care. She is appointed as Professor with Tenure and Associate Chair-Research in the Department of Medicine, McGill University. She is co-Director of the CIHR-funded CanVECTOR Network, a Canadian national venous thromboembolism research and training network. Dr. Kahn’s research interests focus primarily on clinical trials of interventions to prevent, diagnose, treat, and improve outcomes of venous thromboembolism. She holds a Tier 1 Canada Research Chair in Venous Thromboembolism and has published more than 300 papers in the field of thromboembolism.

Guy Young, MD, received his medical degree from the State University of New York at Stony Brook School of Medicine in Stony Brook, New York. He completed a residency in pediatrics at Long Island Jewish Medical Center, Albert Einstein College of Medicine in New York, and a fellowship in pediatric hematology/oncology at Children's National Medical Center in Washington, D.C. He is the Director of the Hemostasis and Thrombosis Center at Children's Hospital Los Angeles and a Professor of Pediatrics at the University of Southern California's Keck School of Medicine. His current research activities encompass clinical trials in hemophilia and the development of the global hemostasis assays in hemophilia. Dr. Young has published many journal articles, abstracts, and textbook chapters and has delivered lectures, workshops, and presentations at national and international meetings. He is the past chair of the Scientific and Standardization Committee on Factor VIII, Factor IX, and Rare Bleeding Disorders of the International Society on Thrombosis and Haemostasis. He has been awarded the National Hemophilia Foundation Physician of the Year Award in 2013.

Dr. Bailey is Director of Physical Therapy/Occupational Therapy at the Los Angeles Lifespan Orthopaedic HTC, Orthopaedic Institute for Children in Los Angeles, California. Previously, she served as Assistant Professor of Clinical Practice in the Department of Physical Therapy at the University of Southern California and Mount St. Mary’s PT Doctorate Program and is the past administrator of the LA Orthopaedic Hospital Sports Care Outreach & Education program. Her post-graduate work includes an advanced residency at Kaiser West LA in Manual Orthopaedic PT and a Doctoral Fellowship at USC’s Keck School of Medicine in Medical Education, Teaching & Learning. Due to her Certified Athletic Training and PT sports specialty backgrounds, she was an invited practitioner for the Pan Am Games, U.S. Olympic teams, the Israeli Macabbi Games, the World Figure Skating Championships, and several national hockey championships. In 2021, she was chosen as the National Hemophilia Foundation’s PT of the year. Dr. Bailey was a lead author for the USA Guidelines for use of “MSKUS in the HTC.” As co-author, she has published articles on MSKUS and in the journals Haemophilia and The Journal of Ultrasonic Medicine. She co-facilitates bi-monthly MSKUS rounds and is teaching faculty in MSKUS use for musculoskeletal problems

Dr. Pruthi is Associate Professor, Mayo Medical School, and a consultant for the Department of Internal Medicine and Hematology/Department of Laboratory Medicine and Pathology. He serves as Director of the Comprehensive Hemophilia Center, Co-Director of the Special Coagulation DNA Diagnostic Laboratory, and Co-Director for Practice at the Special Coagulation Laboratory, Dept of Laboratory Medicine and Pathology at Mayo Clinic in Minnesota. Over the years, Dr. Pruthi has worked with NASCOLA, and along with Dr. William L Nichols, has served as Co-Director of the jointly held NASCOLA/Mayo Bleeding and Thrombosis Coagulation Conference held in Rochester, MN in 2008 and the Coagulation Quality Conference held in Minneapolis, MN in 2007. As Co-Director of the Special Coagulation Laboratory and DNA Diagnostic Laboratory, Dr. Pruthi has expertise in clinical and quality aspects of both coagulation and DNA-based testing, including thrombophilia and bleeding disorders (factor IX and VWF genetic testing). As a member at large, Dr. Pruthi hopes to contribute and collaborate to NASCOLA’s efforts to assure quality in coagulation testing.

Dr. Warren is Assistant Professor at the University of Colorado Anschutz Medical Campus and a pediatric hematologist at the Hemophilia and Thrombosis Center at Children's Hospital Colorado. Her research focus is better understanding the influences of movement patterns on joint and muscle bleeding, with a goal to help patients with bleeding disorders participate safely in sports and physical activities.

Dr. Kumar is Director of the Thrombosis and Anticoagulation Program at Boston Children’s Hospital and Associate Professor of Pediatrics at the Harvard Medical School. After completing medical school at the University of Calcutta, he completed postgraduate training at SUNY Downstate, New York, and the Mayo Clinic, Minnesota. In 2013, Dr. Kumar completed a second fellowship in Pediatric Thrombosis/Hemostasis at the Hospital for Sick Children, Ontario, Canada. Dr. Kumar is a recipient of the Young Researcher Award from the World Federation of Hemophilia, the Eberhard Mammen Young Investigator Award for Excellence in Hemostasis and Thrombosis, and the Mentored Research Award from the Hemostasis and Thrombosis Research Society. He has published over 50 peer-reviewed papers and 10 book chapters in pediatric hemostasis and thrombosis.

Dr. Mullins is Associate Professor of Pediatrics at Cincinnati Children's Hospital Medical Center. His research focuses on achieving a better understanding of hemostatic factors, both in the setting of hemostasis/thrombosis and in regard to how these factors interact with other diseases and physiologic conditions. His laboratory concentrates on the role(s) of fibrin deposition and clearance in neuroinflammation. Dr. Mullins's clinical career is centered on taking care of children and adolescents with bleeding disorders and thrombosis. Dr. Mullins also partners with his wife, Dr. Tanya Mullins (adolescent medicine) to prospectively understand the thrombosis risk associated with gender-affirming hormone therapy.

Dr. Aslan is Associate Professor at Oregon Health & Science University, where he leads basic and translational studies of platelet function.

Dr. Huffman serves as Scientific Director for Genomics Research in the Center for Population Genomics within the Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC) at VA Boston Healthcare System. She is also Assistant Professor of Medicine at Harvard Medical School. Dr. Huffman’s initial training was in molecular biology and genetics at the University of Guelph, Ontario, Canada. She then completed a Masters degree in Quantitative Genetics and Genome Analysis and a PhD in Molecular Medicine at the University of Edinburgh. Dr. Huffman completed her training as an NHLBI Postdoctoral Fellow with the Framingham Heart Study, focusing on cardiovascular and platelet genetics. Dr. Huffman's research interests lie in understanding genetic contributors to thrombosis and hemostasis, including characteristics of blood cells and blood clotting factors. Her current research is with the VA Million Veteran Program focused on underrepresented populations. She has a strong interest in collaborations to take statistical findings to in vivo experiments to better understand biology and move findings closer to clinical translation.

Dr. Crowther is Chair of the Department of Medicine at McMaster University. His major areas of research are in the management of patients with antiphospholipid antibodies, the prevention of venous thrombosis in patients in the intensive care unit, studies examining optimal management of both parenteral and oral anticoagulants, and defining best practices in the use of vitamin K in patients with excess warfarin effect. Dr. Crowther has more than 500 peer-reviewed publications with an H factor of more than 115 (Google Scholar) and has presented at more than 550 major events worldwide, including the American Heart Association, American Society of Hematology, American Society of Clinical Oncology, and the International Society of Thrombosis and Haemostasis. He was inducted into the Royal Society of Canada in recognition of his research and humanitarian work in Uganda.

Tom DeLoughery, MD, MACP, FAWM is Professor of Medicine, Pathology and Pediatrics at the Oregon Health & Science University.  He is is a native Hoosier who graduated from Indiana State University one year after Larry Bird and received his MD at Indiana University School of Medicine. He did his internship at the University of California, Irvine before traveling to Oregon where he finished his internal medicine residency and hematology/oncology fellowship at Oregon Health & Science University (OHSU). His clinical interests are in iron deficiency, general hematology, and coagulation, subjects on which he has written extensively and the basis of his clinical practice. He has won numerous teaching awards and was course director for the medical school Blood Course for ten years. He also has an interest in the hematologic aspects of Wilderness Medicine. He served six years on the board of directors of the Wilderness Medicine Society and currently chairs their research committee.  

Dr. Moll received his medical degree from Freiburg University in Germany. He completed his internship, residency, and fellowship in internal medicine and hematology/oncology at Duke University Medical Center in North Carolina, along with a one-year Clinical Coagulation Fellowship at the University of North Carolina at Chapel Hill. Dr. Moll is a faculty member at UNC in the Department of Medicine/Division of Hematology since 1999. His clinical interest is coagulation and classical hematology, with a particular focus on thrombosis and anticoagulation. Dr. Moll’s research interests include clinical trials on new anticoagulants and better use of established anticoagulants. He takes special interest in the clinical-medical education of patients, the public, and healthcare professionals. His four main professional goals for the next 5-10 years are: (1) to enhance national and local health care provider and patient education activities on venous thromboembolism, (2) to continue to build an “Athletes and Blood Clot Program”, (3) to support trainees in their career development in the field of coagulation/hematology, and (4) to work on identifying the etiology and best treatment of livedoid vasculopathy.

Nathan Connell is an associate physician in the Hematology Division at Brigham and Women’s Hospital, Associate Professor of Medicine at Harvard Medical School, and Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital where his clinical practice focuses on clotting and bleeding disorders and he researches cost-effective strategies for diagnosis and management of hematologic disorders. A graduate of Cornell University, the University of Miami School of Medicine, and the Harvard School of Public Health, he completed an internal medicine residency and a hematology/oncology fellowship at Brown University.

Dr. Vanhoorelbeke is full professor at KU Leuven, Belgium. Her research focuses on the molecular mechanisms by which the hemostatic proteins von Willebrand factor (VWF) and its cleaving enzyme ADAMTS13 contribute to health and disease (https://thrombosis.kuleuven-kulak.be). She is co-founder of the KU Leuven Antibody Center PharmAbs (https://www.kuleuven-kulak.be/pharmabs/). In 2010, she completed a 9-month sabbatical at Harvard Medical School in the lab of Dr. Tim Springer. Her research is embedded in several national and international research projects. Recently, she was awarded a Horizon2020 Marie Curie Training Network Grant ‘PROFILE’ of which she is the coordinator (http://www.itn-profile.eu). She is author and co-author of more than 185 scientific publications in international peer-reviewed journals and is co-promotor of 32 PhD students. She was awarded 8 national and international prizes, has 4 patents, and one diagnostic assay on the market.

Dr. Zheng is the Russell J. Eilers, MD Professor and Chair of Pathology and Laboratory Medicine at The University of Kansas Medical Center (KUMC). Dr. Zheng completed his medical degree at Nanchang University, China, and his PhD at the University of Vienna, Austria. Following his residency in pathology and fellowship in transfusion medicine and hemostasis at Barnes-Jewish Hospital/Washington University in St. Louis, Missouri, Dr. Zheng accepted his first faculty position at the University of Pennsylvania, Philadelphia, and quickly rose to the rank of tenured Associate Professor. Dr. Zheng was recruited to UAB, where he served as the Division Director of Laboratory Medicine. In early 2020, Dr. Zheng was named Chair and Service Chief in Pathology and Laboratory Medicine at KUMC. Dr. Zheng's research focuses on pathogenesis of thrombotic thrombocytopenic purpura (TTP). He and his colleagues have published more than 125 manuscripts in peer-reviewed journals and six book chapters. Dr. Zheng is a standing member of the Hemostasis, Thrombosis, and Blood Transfusion (HTBT) study section at the National Institute of Health.

Dr. Ahamed is an Associate Member of the Cardiovascular Biology Research Program at Oklahoma Medical Research Foundation. His lab efforts focus on the role of platelet-derived factors in organ fibrosis and thrombotic complications associated with cardiovascular disease.

Dr. Pai is Professor of Medicine at McMaster University, Chief of Laboratory Medicine at Hamilton Health Sciences and St. Joseph's Healthcare in Hamilton, Medical Director of the Hamilton Regional Laboratory Medicine Program, and Head of Service for Benign Hematology at Hamilton Health Sciences in Canada. Dr. Pai completed her medical training at McMaster University and the University of Toronto. She holds a Masters in Health Research Methodology and has practiced as a hematologist and thrombosis medicine physician at Hamilton Health Sciences since 2008. She is also a member of McMaster University’s Thrombosis and Atherosclerosis Research Institute (TAARI) and the McMaster Centre for Transfusion Research (MCTR). Dr. Pai’s clinical interests focus on benign hematology, particularly thrombotic and bleeding disorders. Her research interests include venous thromboembolism, research methods in rare diseases, clinical practice guideline development, knowledge translation, and quality improvement.

Dr. Ahmadzia is a specialist in Maternal-Fetal Medicine and Assistant Professor in the Department of Obstetrics and Gynecology. Dr. Ahmadzia completed her undergraduate degree, medical school education, and a Masters of Public Health at The George Washington University. She then completed her residency at Yale University and her fellowship in Maternal-Fetal Medicine at Duke University. Dr. Ahmadzia previously received the Clinical and Translational Science Institute KL2 Mentored Career Development Award through the GW-CNMC partnership with NIH. She is currently working on a K23 Career Mentored Development Award from NHLBI about optimizing the dose of tranexamic acid for the prevention of postpartum hemorrhage. She has a specific clinic for Pregnancy and Hematology issues at George Washington University. She also has other grant-funded research from the FDA and the Gates Foundation. She serves as the Medical Monitor for the Maternal-Fetal Medicine Unit Network and is a member of the Society of Maternal Fetal-Medicine Global Health Committee.

Dr. Rosovsky is a board-certified hematologist at Massachusetts General Hospital (MGH), Assistant Professor of Medicine at Harvard Medical School (HMS), Director of Thrombosis Research in the Division of Heme, and Co-Chair of MGH’s Thrombosis Committee. She earned a BA from University of Pennsylvania, an MD from HMS, and an MPH from the Harvard School of Public Health. She completed residency at Brigham & Women's Hospital and fellowship in heme/onc at Dana-Farber Cancer Institute’s MGH Program. Dr. Rosovsky is founder and President-Elect of the Pulmonary Embolism Response Team (PERT) Consortium. She also serves on the Executive Committee of MGH PERT, and is the creator/director of the PERT Multidisciplinary Follow-up Clinic. She serves on the Medical/Scientific Advisory Board for National Blood Clot Alliance, the Executive Committee for VTE Network US, and the Committee on Quality for ASH. She has collaborated worldwide with researchers on risks, diagnosis, and treatment of VTE, has published widely, and has presented her work at scientific conferences worldwide in these topic areas. Through lecturing, research, and written works, she has sought to improve care for patients with VTE and advance understanding and treatment of VTE for 15+ years.

Dr. Pawlinski is Professor of Medicine at the University of North Carolina at Chapel Hill. He earned his graduate degree at the Jagiellonian University in Krakow, Poland, and obtained postdoctoral training at the Scripps Research Institute in La Jolla, California. In 2008, he joined the Division of Hematology at the University of North Carolina at Chapel Hill to continue his research in the field of thrombosis, hemostasis, and inflammation. Shortly thereafter, he was awarded the Kenneth Brinkhous Young Investigator Prize in Thrombosis from the American Heart Association. Dr. Pawlinski and his team are interested in the role of coagulation proteases in the pathology of cardiovascular, neurological, and hematological diseases. Over the last 10 years, a significant portion of his research has focused on sickle cell disease, specifically the role of coagulation proteases in the pathology of this disease and understanding the mechanisms of coagulation activation and venous clot formation.

Dr. Pecker is Assistant Professor of Medicine at Johns Hopkins University School of Medicine, where she directs the Clinic for Young Adults at the Johns Hopkins Sickle Cell Center for Adults.

Dr. Batsuli is Assistant Professor in the Department of Pediatrics and the Division of Pediatric Hematology and Oncology at Emory University. She received her Bachelors of Science in Public Health in Nutrition with a minor in Chemistry from the University of North Carolina at Chapel Hill. Following her undergraduate education, she earned her medical degree from the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania. Dr. Batsuli completed her pediatric residency and pediatric hematology and oncology fellowship at Emory University in Atlanta, Georgia. She treats children with bleeding and clotting disorders as a member of the Hemostasis and Thrombosis team with the Aflac Cancer and Blood Disorders Center at Emory University and at Children’s Healthcare of Atlanta. Her primary research focus is evaluating the innate immune response against blood coagulation proteins factor VIII and factor IX.

Dr. Kucine is Associate Professor of Clinical Pediatrics in the Division of Hematology/Oncology at Weill Cornell Medicine. She completed her pediatric hematology/oncology fellowship at the combined program of Memorial Sloan Kettering Cancer Center and New York-Presbyterian Hospital/Weill Cornell Medicine. She joined the faculty in the Department of Pediatrics at Weill Cornell Medicine in 2011. Dr. Kucine’s research and clinical interests include thrombosis in special pediatric populations, including children with cancer or inflammatory bowel disease, and myeloproliferative neoplasms in children.

Katherine Regling DO is Assistant Professor in Pediatric Hematology Oncology at Children's Hospital of Michigan/Central Michigan University.  She has been involved in several clinical projects involving global coagulation assays and thromboinflammatory markers.  Her current work involves evaluating these biomarkers in children with hemophilia A, as well as in critically ill patients that require extra-corporeal membrane oxygenation (ECMO) therapy. She has received research funding through the HTRS/Novo-Nordisk Clinical Fellowship Award, Ashok and Ingrid Sarnaik Junior Faculty Endowment Grant, and the Hemophilia of Georgia Clinical Scientist Development Grant.
 

Dr. Haley is Associate Professor of Pediatrics in the Division of Pediatric Hematology/Oncology at Oregon Health & Science University. She is Director of the Hemophilia Center at OHSU. In addition, she co-directs the OHSU Spots, Dots, & Clots Clinic, which is a combined hematology/gynecology clinic for adolescents with bleeding and clotting disorders. Dr. Haley spends time educating medical students, residents, fellows, and community health care providers on all things related to non-malignant hematology, with emphasis on the care of women and girls with blood disorders. Dr. Haley’s research includes projects aimed at characterizing the symptoms, treatments, and impacts of bleeding in women with bleeding disorders through a national dataset, as well as improving public understanding of platelet disorders.

Dr. Li is Professor of Pediatrics with tenure and the Andrew Glaub Research Chair at Emory University School of Medicine. His research interest centers on the structure, function, and regulation of platelet receptors and ligands in the context of thrombotic and thrombocytopenic diseases. He received a BS in Biochemistry from Nanjing University, a PhD in Biochemistry and Biophysics from University of Minnesota, and completed postdoctoral training in Biophysics and Hematology at University of Pennsylvania School of Medicine. Dr. Li became Assistant Professor and established his research lab at University of Texas Health Science Center at Houston in 2003, and moved to Emory University in 2011. He has published more than 80 research articles, most of which are on the platelet GPIb-IX receptor complex and its ligand VWF. He has served on a number of review panels and committees and is currently a member of the American Society of Hematology Awards Committee and Co-Chair of the Scientific and Standardization Committee on VWF for the International Society on Thrombosis and Haemostasis.

Brian Branchford, MD is Associate Medical Director, Comprehensive Center for Bleeding Disorders at Medical Sciences Institute Versiti and Associate Investigator in Thrombosis and Hemostasis at Blood Research Institute Versiti. After completing his Pediatrics Residency at Medical College of Wisconsin, he completed his postdoctoral training at University of Colorado School of Medicine. Dr. Branchford is a physician-scientist building an academic career in basic-translational research in non-malignant hematology, with a focus on pediatric thrombosis. The overall goal of his research is to define the role of platelet activation in thromboinflammation as a means to identify biomarkers for risk stratification, as well as potential novel approaches to thrombosis treatment or prevention. As a research fellow and junior faculty hematologist, he studied basic/translational aspects of the mechanisms that determine platelet activation using a variety of in vitro functional assays and relevant animal models.

Dr. Cardenas is Assistant Professor in the Department of Surgery at the University of Texas Health Science Center at Houston. Her research focuses on mechanisms of traumatic coagulopathy, endothelial pathways that drive thromboinflammation following hemorrhagic shock, and identifying best transfusion practices and novel therapeutics for preventing hemorrhage-related deaths and thromboinflammatory complications secondary to traumatic hemorrhage.

Mitchell Cohen is Professor of Surgery at the University of Colorado. Clinically he is an active Trauma, General, and Acute Care Surgeon as well as a busy Intensivist. Dr. Cohen has an active NIH and DoD-funded basic science research lab, which studies coagulation and inflammation perturbations after trauma. His lab continues to examine the mechanisms of traumatic coagulopathy and mediators of protein C  activation after trauma. In addition to its basic science focus the Cohen research group studies similar topics through multiple clinical characterization and interventional trials aimed at elucidating the post-trauma coagulation milieu and optimal resuscitation. Finally, the Cohen group has an active interest in silico data and model-driven approaches to the modeling of biological and physiologic systems. In keeping with this, his group has done work on the use of Big Data towards improving personalized medicine and outcomes. His work includes multi-scale modeling projects ranging from coagulation and endothelial biology to causal inference prediction of patient physiologic state and trajectory. His best job however is as Dad to Ava (16) and husband to Stephanie.

"

Jing-fei Dong, MD, PhD is a member of the Bloodwork Research Institute and Professor of Medicine in the Division of Hematology at the University of Washington School of Medicine. He received clinical training in neurosurgery from Tianjin Medical University in China and Birmingham University in the UK through a combined clinical fellowship. He received research training in hemostasis and thrombosis from Gladstone Institute of Cardiovascular diseases, UCSF, and Baylor College of Medicine. One of his research focuses is on bleeding and thrombotic complications of non-classical hematological diseases, including traumatic brain injury, particularly pathways to the TBI-induced systemic hypercoagulable state and resultant coagulopathy, and patients supported by left ventricular assist devices. His basic science research is focused on the structure-functional correlations between the adhesive ligand VWF and its cleaving metalloprotease ADAMTS-13 for regulating hemostasis and thrombosis. His research is primarily funded by NIH and foundation grants and is reported in 236 peer-reviewed publications.